Side-by-side comparison of AI visibility scores, market position, and capabilities
AI pharma drug launch platform compressing market access research from months to minutes; six-figure ARR within weeks of launch with Bayer as client across 12 markets.
Cellbyte is an AI-powered pharmaceutical drug launch platform that accelerates global drug launches by providing real-time pricing and market access intelligence — compressing processes that traditionally take months or years (reference pricing analysis, health technology assessment research, payer landscape mapping) into minutes using AI-driven data aggregation and analysis. Founded in 2024 and a Y Combinator graduate, Cellbyte raised $2.75 million in seed funding led by Frontline Ventures and Y Combinator, achieving six-figure ARR within weeks of launch.\n\nCellbyte's platform aggregates regulatory approval data, drug pricing reference lists, payer coverage policies, and health technology assessment outcomes across multiple countries to help pharmaceutical market access teams make faster, better-informed launch sequence decisions. Global drug launches require navigating distinct pricing and reimbursement systems in each country — reference pricing (where one country's price affects another's) makes launch sequencing strategically critical and data-intensive. Cellbyte automates the research that market access consultants previously performed manually.\n\nIn 2025, Cellbyte secured major clients including Bayer across 12 live markets — demonstrating enterprise adoption velocity unusual for a seed-stage company. The pharmaceutical market access software market includes specialized players like IQVIA (market data), ZS Associates (consulting), and early-stage AI entrants. The total addressable market is substantial given the global pharmaceutical market's hundreds of billions in annual drug launches. Cellbyte's 2025-2026 strategy focuses on expanding the breadth of markets covered (targeting all major pharma markets globally), deepening AI capabilities for predictive pricing modeling, and growing its pharmaceutical client base beyond the initial anchor customers.
AI chemical reaction optimization with 95% accuracy for drug discovery synthesis parameters; $4.5M from Khosla Ventures and YC competing to automate pharmaceutical process chemistry development.
Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists with AI systems that determine optimal reaction parameters (temperature, solvent, catalyst, concentration) for new chemical synthesis routes, achieving 95% accuracy in suggesting effective conditions for small-scale trials. Founded in 2023 and backed by Khosla Ventures, 468 Capital, 500 Global, and Y Combinator with $4.5 million raised including a $4 million seed round in April 2024, Yoneda Labs brings mathematical category theory foundations (the name references Yoneda's lemma in category theory) to chemistry AI.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.